InsiderTrades.com logo
Nadim Ahmed net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Nadim Ahmed Biography and Net Worth

President and Chief Executive Officer of Cullinan Therapeutics

Nadim has more than twenty-five years of leadership experience across a range of development and commercialization roles, including recently at Bristol Myers Squibb, where he served as President, Hematology and at Celgene Corporation where he served as President, Global Hematology & Oncology. At Bristol Myers Squibb, Nadim oversaw multiple product launches and served as a member of the company’s Leadership Team. Prior to Bristol Myers Squibb, Nadim served in leadership roles at Celgene across both development and commercialization functions.

Nadim has expertise in various treatment modalities, including small molecules, biologics, and cell therapy.

What is Nadim Ahmed's net worth?

The estimated net worth of Nadim Ahmed is at least $4.56 million as of February 25th, 2025. Ahmed owns 430,621 shares of Cullinan Therapeutics stock worth more than $4,555,970 as of December 4th. This net worth approximation does not reflect any other investments that Ahmed may own. Additionally, Ahmed receives a salary of $1,160,000.00 as President and Chief Executive Officer at Cullinan Therapeutics. Learn More about Nadim Ahmed's net worth.

How old is Nadim Ahmed?

Ahmed is currently 56 years old. There are 6 older executives and no younger executives at Cullinan Therapeutics. Learn More on Nadim Ahmed's age.

What is Nadim Ahmed's salary?

As the President and Chief Executive Officer of Cullinan Therapeutics, Inc., Ahmed earns $1,160,000.00 per year. Learn More on Nadim Ahmed's salary.

How do I contact Nadim Ahmed?

The corporate mailing address for Ahmed and other Cullinan Therapeutics executives is , , . Cullinan Therapeutics can also be reached via phone at 617-410-4650 and via email at [email protected]. Learn More on Nadim Ahmed's contact information.

Has Nadim Ahmed been buying or selling shares of Cullinan Therapeutics?

Nadim Ahmed has not been actively trading shares of Cullinan Therapeutics over the course of the past ninety days. Most recently, Nadim Ahmed sold 12,529 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $8.53, for a transaction totalling $106,872.37. Following the completion of the sale, the chief executive officer now directly owns 430,621 shares of the company's stock, valued at $3,673,197.13. Learn More on Nadim Ahmed's trading history.

Who are Cullinan Therapeutics' active insiders?

Cullinan Therapeutics' insider roster includes Nadim Ahmed (Pres), Nadim Ahmed (President and Chief Executive Officer), Ansbert Gadicke (Director), Jeffrey Jones (Chief Medical Officer), Jennifer Michaelson (Insider), Corrine Savill (Chief Business Officer), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider). Learn More on Cullinan Therapeutics' active insiders.

Are insiders buying or selling shares of Cullinan Therapeutics?

During the last twelve months, Cullinan Therapeutics insiders bought shares 8 times. They purchased a total of 1,874,057 shares worth more than $13,325,286.34. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 42,006 shares worth more than $444,804.13. The most recent insider tranaction occured on November, 24th when insider Jennifer Michaelson sold 4,000 shares worth more than $49,200.00. Insiders at Cullinan Therapeutics own 7.2% of the company. Learn More about insider trades at Cullinan Therapeutics.

Information on this page was last updated on 11/24/2025.

Nadim Ahmed Insider Trading History at Cullinan Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/25/2025Sell12,529$8.53$106,872.37430,621View SEC Filing Icon  
12/24/2024Sell8,400$11.87$99,708.00263,150View SEC Filing Icon  
12/26/2023Sell4,272$9.24$39,473.28111,550View SEC Filing Icon  
6/28/2023Sell759$11.40$8,652.60115,822View SEC Filing Icon  
5/23/2023Sell707$9.15$6,469.05116,581View SEC Filing Icon  
4/25/2023Sell716$10.59$7,582.44117,288View SEC Filing Icon  
3/23/2023Sell706$10.51$7,420.06118,004View SEC Filing Icon  
6/6/2022Buy8,090$12.40$100,316.008,090View SEC Filing Icon  
See Full Table

Nadim Ahmed Buying and Selling Activity at Cullinan Therapeutics

This chart shows Nadim Ahmed's buying and selling at Cullinan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cullinan Therapeutics Company Overview

Cullinan Therapeutics logo
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $10.58
Low: $10.08
High: $10.79

50 Day Range

MA: $8.26
Low: $5.75
High: $12.93

2 Week Range

Now: $10.58
Low: $5.68
High: $13.60

Volume

877,985 shs

Average Volume

1,211,674 shs

Market Capitalization

$625.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A